Abstract 2583
Background
Multimodality treatment offers promising results in patients with histopathological proven pelvic lymph node metastatic (pN1) prostate cancer. Improved cause-specific survival rates are reported when treating the primary tumor combined with whole pelvic radiotherapy and androgen deprivation therapy (ADT) compared to ADT alone. However, in case of tumoral invasion of > 1 pelvic lymph node, approximately 40% of the patients relapse biochemically and clinically. This clinical relapse is located in the para-aortic lymph nodes (M1a disease) in up to 77% of relapsed cases. We hypothesize that adding elective para-aortic radiation will reduce the development of both retroperitoneal nodal (M1a) and distant metastasis (M1b/M1c), postpone the need for palliative ADT and prolong the time to castration-refractory disease.
Trial design
This is a multicenter, non-randomized phase 2 trial (NCT03079323) conducted in 5 sites in Belgium. Men are eligible for the study when (1) age >18 years, (2) histological proven adenocarcinoma of the prostate at biopsy (cT1-4) and referred for primary high-dose radiotherapy or after radical prostatectomy (pT2-4), and (3) presence of pN1 disease after extended pelvic lymph node dissection. If pN1 disease is present, patients are eligible if one of the following criteria is fulfilled: ≥ 2 positive lymph nodes, a ratio positive / removed lymph nodes > 7% or presence of extracapsular metastatic extension at the level of any lymph node. Patients will receive radiotherapy on the prostate (bed), pelvic lymph nodes and the para-aortic lymph nodes combined with 24 months of ADT. We aim to include 137 patients to detect an improvement in clinical relapse free survival (cRFS) by 15% at 5 years (power of 80%).
The primary endpoint is 5 year-clinical relapse-free survival (cRFS) defined as the absence of any clinical relapse that would be visible at top of the line imaging. Secondary endpoints are Quality of life (QoL), treatment-related acute and late toxicity, time to palliative ADT, time to castration refractory prostate cancer (CRPC), cause-specific survival (CSS) and in field pelvic and para-aortic disease control. Recruitment is ongoing, with the first patient included in the trial on 06/02/2017.
Clinical trial identification
NCT03079323.
Legal entity responsible for the study
University Hospitals Leuven, Belgium.
Funding
“Kom op tegen kanker (Stand up to Cancer), the Flemish Cancer Society”. (ref. 0010048).
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1449 - Prognostic factors associated with pathological complete response in early breast cancer patients undergoing neoadjuvant chemotherapy. The importance of Ki-67 and molecular subtype.
Presenter: Bernardo Rapoport
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4023 - The accuracy of sentinel lymph node biopsy following neoadjuvant chemotherapy in clinically node positive breast cancer patients: A single institution experience
Presenter: Narges Sistany Allahabadi
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4707 - Index BRCA1/2 testing under a multidisciplinary program
Presenter: Duarte Machado
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3393 - BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients
Presenter: Alex Friedlaender
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3175 - PALB2 germ-line mutations in Russian breast cancer patients: identification of recurrent alleles and analysis of phenotypic characteristics of the tumors
Presenter: Evgeny Imyanitov
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3027 - Landscape of germline mutations in hereditary breast and ovarian cancer (HBOC) patients in Russia revealed by target panel sequencing
Presenter: Elena Shagimardanova
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4963 - Lynch syndrome-associated hereditary mutations cause breast and ovarian cancer: results from Russian Heredetary Oncogenomics project
Presenter: Marat Gordiev
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2916 - Impact of deleterious germline BRCA mutations, addition of taxanes and use of adjuvant endocrine therapy (ET) on anti-müllerian hormone (AMH) levels in early breast cancer (EBC) patients treated by adjuvant chemotherapy (CT)
Presenter: Nathalie OLYMPIOS
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2400 - Germline mutation status and therapy response in patients with triple-negative breast cancer (TNBC): Results of the GeparOcto study
Presenter: Esther Pohl
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
1345 - BRCA1/BRCA2 Predictive Genetic Testing in an Irish Population: A Missed Opportunity
Presenter: David O Reilly
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract